OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders Annual General Meeting of September 30, 2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General…
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
KFSHRC to Partake Tomorrow as Strategic Partner in C3 Davos of Healthcare New York Summit
NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80%…
Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community
SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper…
Helios Alliance Announces National Opioid Conference Featuring Former White House Drug Policy Director Dr. Rahul Gupta
September 05, 2025 16:45 ET | Source: Helios Alliance Mobile, Alabama ,…
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program…
SAIL signs MoU with The Art of Living to Enhance Employee Well-being, Leadership Belongingness
BENGALURU, India, Sept. 5, 2025 /PRNewswire/ -- Steel Authority of India Limited…
Fitterfly Launches ‘Uplift’ – A Mental Wellness Program for Students and Communities
MUMBAI, India, Sept. 4, 2025 /PRNewswire/ -- A recent national study across nine…